Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Priming Clear all
Completed Phase 1 Interventional

Vaccine for Prevention of Bird Flu

NCT00776711
View directory record Official record
Conditions
Influenza, Human
Interventions
Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of HPN424 in Patients With Advanced Prostate Cancer

NCT03577028
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target, HPN424 2 Prime Step IV 300 ng/kg Target, HPN424 2 Prime Step IV 450 ng/kg Target, HPN424 Fixed SC
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Priming and Patient Reported Outcome Measures

NCT05229016
View directory record Official record
Conditions
Patient Participation, PROM
Interventions
Reflection on health-related experiences
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)

NCT07089953
View directory record Official record
Conditions
Communication Skills, Professionalism, Randomized Controlled Trial, Perception
Interventions
Questionnaire, Video
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
View directory record Official record
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

NCT05322850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
Interventions
Orca-Q
Biological
Lead sponsor
University of Florida
Other
Eligibility
Up to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676
View directory record Official record
Conditions
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions
ONCOS-102, Cyclophosphamide, Pembrolizumab
Biological · Drug
Lead sponsor
Targovax Oy
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Penile Nerve Stimulation for Treatment of Delayed Ejaculation

NCT04115540
View directory record Official record
Conditions
Delayed Ejaculation
Interventions
TENS penile nerve stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 8:08 AM EDT
Terminated Phase 3 Interventional

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

NCT02019589
View directory record Official record
Conditions
Secondary Amenorrhea
Interventions
Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
22
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 18, 2026, 8:08 AM EDT
Terminated Not applicable Interventional

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

NCT00253552
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm

NCT07224308
View directory record Official record
Conditions
Laxity; Skin
Interventions
Ultherapy Prime
Device
Lead sponsor
The Levine Center for Plastic Surgery
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

NCT06653387
View directory record Official record
Conditions
Carotid Artery Diseases
Interventions
CGuard Prime 80cm stent system
Device
Lead sponsor
InspireMD
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Sacramento, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 18, 2026, 8:08 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H9 Priming Study in Healthy Adults

NCT00617331
View directory record Official record
Conditions
Influenza
Interventions
Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Results available

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

NCT03558139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Magrolimab, Avelumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Results available

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03805594
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions
Lutetium Lu 177-PSMA-617, Pembrolizumab
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 18, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

NCT07113041
View directory record Official record
Conditions
Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions
Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 18, 2026, 8:08 AM EDT
Not listed Not applicable Interventional

Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports

NCT01927523
View directory record Official record
Conditions
Youth Violence, Crime, Educational Achievement
Interventions
BAM, Match
Behavioral · Other
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
5,344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Not applicable Interventional

Feasibility of Video Gaming Technology for Arm Recovery Early Post-stroke

NCT06691880
View directory record Official record
Conditions
Subacute Stroke, Acute Stroke
Interventions
MindPod Dolphin VGT, Bimanual Arm Trainer VGT
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 18, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient

NCT01816477
View directory record Official record
Conditions
Pectus Excavatum
Interventions
ON-Q soaker catheter system, Epidural (ropivicaine 0.25%)
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 18, 2026, 8:08 AM EDT